Minutes of PPAR-γ agonism and neuroprotection.
1. Neurochem Int. 2020 Nov;140:104814. doi: 10.1016/j.neuint.2020.104814. Epub 2020 Aug 3. Minutes of PPAR-γ agonism and neuroprotection. Prashantha Kumar BR(1), Kumar AP(2), Jose JA(2), Prabitha P(1), Yuvaraj S(1), Chipurupalli S(2), Jeyarani V(2), Manisha C(2), Banerjee S(2), Jeyabalan JB(2), Mohankumar SK(3), Dhanabal SP(3), Justin A(4). Author information: (1)Department of Pharmaceutical Chemistry, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Mysuru, Karnataka, India. (2)Department of Pharmacology, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, Tamilnadu, India. (3)TIFAC CORE in HD, Department of Pharmacognosy, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, Tamilnadu, India. (4)Department of Pharmacology, JSS Academy of Higher Education & Research, JSS College of Pharmacy, Ooty, Nilgiris, Tamilnadu, India. Electronic address: justin@jssuni.edu.in. Peroxisome proliferator-activated receptor gamma (PPAR-γ) is one of the ligand-activated transcription factors which regulates a number of central events and considered as a promising target for various neurodegenerative disease conditions. Numerous reports implicate that PPAR-γ agonists have shown neuroprotective effects by regulating genes transcription associated with the pathogenesis of neurodegeneration. In regards, this review critically appraises the recent knowledge of PPAR-γ receptors in neuroprotection in order to hypothesize potential neuroprotective mechanism of PPAR-γ agonism in chronic neurological conditions. Of note, the PPAR-γ's interaction dynamics with PPAR-γ coactivator-1α (PGC-1α) has gained significant attention for neuroprotection. Likewise, a plethora of studies suggest that the PPAR-γ pathway can be actuated by the endogenous ligands present in the CNS and thus identification and development of novel agonist for the PPAR-γ receptor holds a vow to prevent neurodegeneration. Together, the critical insights of this review enlighten the translational possibilities of developing novel neuroprotective therapeutics targeting PPAR-γ for various neurodegenerative disease conditions. Copyright © 2020 Elsevier Ltd. All rights reserved. DOI: 10.1016/j.neuint.2020.104814 PMID: 32758586 [Indexed for MEDLINE]